Home > Insider Trading > Filing (0001209191-12-033063)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1344413	Alexza Pharmaceuticals Inc.	ALXA	Pharmaceutical Preparations (2834)	770567768

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1353528	V James Cassella	Alexza Pharmaceuticals Inc. 2091 Stierlin Court Mountain View CA 94043	Svp, Research & Development	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2012-06-06	46,222	$0.34	157,801	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Footnotes

Represents shares issued as restricted stock units (an "RSU") under the Issuer's 2005 Equity Incentive Plan (the "Plan") that vested in full on June 5, 2012. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2012.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.3249 to $0.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Includes, as previously reported: (i) 100,000 RSUs granted under the Plan that will vest in full on August 24, 2012, provided that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan prior to such time, and (ii) 45,582 RSUs granted under the Plan pursuant to the terms of the Issuer's 2009-2010 Performance Based Incentive Program that will vest on the date the U.S. Food and Drug Administration approves the Issuer's New Drug Application for its ADASUVE (Staccato loxapine) product candidate, if ever, provided that at the relevant vesting date the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.